An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. | Clin Ther;35(6): 782-94, 2013 Jun. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.

Baird-Bellaire, Susan; Behrle, Jessica A; Parker, Vernon D; Patat, Alain; Paul, Jeffrey; Nichols, Alice I.

Affiliation

Baird-Bellaire S; Pfizer, Early Development and Clinical Pharmacology, Paris, France.

Clin Ther ; 35(6): 782-94, 2013 Jun.

Article in En | MEDLINE | ID: mdl-23623756

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurotransmitter Uptake Inhibitors / Cyclohexanols / Liver / Liver Diseases / Antidepressive Agents Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2013 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurotransmitter Uptake Inhibitors / Cyclohexanols / Liver / Liver Diseases / Antidepressive Agents Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2013 Document type: Article Affiliation country: Country of publication: